Hormonal
Obesity induces systemic oxidative stress and chronic low-grade inflammation through adipose tissue dysfunction, specifically via increased adipokine secretion (leptin, TNF-α, IL-6) and mitochondrial ROS production, which leads to endothelial dysfunction and insulin resistance.
Recognize that excess body fat, especially visceral fat, is biologically active and drives inflammation and metabolic issues. This is not just 'extra weight' but a source of hormones that disrupt your body's balance. Addressing obesity requires managing this hormonal output, not just counting calories.
Because adipose tissue is the organ that secretes adipokines and these in turn generate ROS, adipose tissue is considered an independent factor for the generation of systemic OS... high ROS production and the decrease in antioxidant capacity leads to various abnormalities, among which we find endothelial dysfunction... favoring atherosclerotic disease.
Why this rating
This is a review paper summarizing multiple studies; it establishes strong mechanistic consensus but lacks a single primary clinical trial.
Source
Inflammation, Oxidative Stress, and Obesity
Alba Fernández-Sánchez et al. · International Journal of Molecular Sciences · 2011
DOI 10.3390/ijms12053117
More from this paper
- Weight loss reduces circulating levels of pro-inflammatory adipokines (leptin, TNF-α, IL-6) and improves endothelial function, thereby mitigating oxidative stress and cardiovascular risk.Moderate
- Dietary patterns high in fat and carbohydrates exacerbate oxidative stress and inflammation in obese individuals, while antioxidant intake (e.g., fruit) may mitigate lipid peroxidation.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →